Alpine Im­mune Sci­ences, Janux said to be look­ing at pos­si­ble sales — re­ports

Two clin­i­cal-stage biotechs are po­ten­tial­ly the next ac­qui­si­tion tar­gets in bio­phar­ma, ac­cord­ing to Wednes­day af­ter­noon re­ports from Bloomberg News.

T cell en­gager biotech Janux Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.